Anti-Viral Effect of an Extract of Ganoderma Lucidum

• US 20080214442A1
• Filed: 09/21/2007
• Published: 09/04/2008
• Est. Priority Date: 09/21/2006
• Status: Abandoned Application

• Current Assignee: Academia Sinica (Government of The Republic of China)
• Original Assignee: Academia Sinica (Government of The Republic of China)
• Inventors: Wong, Chi-Huey, Yu, Alice, Jan, Jia Tsrong, Cheng, Y.-S. Edmond
• Application Number:
  US11/859,729
• Publication Number:
  US 20080214442A1
• Time in Patent Office: Days
• US Class Current: 514/8
• CPC Class Codes: A61K 36/074 Ganoderma
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C07K 2/00 Peptides of undefined number of amino acids; Derivatives thereof

Abstract

Compositions and methods for the treatment viral infections in organisms, particularly flu virus. The methods and compositions of the disclosure involve the administration to mammals and immune cells of a fucose-containing glycoprotein fraction from Reishi. An extract of G. lucidum induces immune responses that are shown to induce increase survivability in mice injected with lethal does of influenza virus. The effect is increased when the G. lucidum extract is dosed prior to injection of the lethal dose of influenza virus.

Claims

1. A composition comprising:

a fucose-containing glycoprotein extract of Ganoderma lucidum;

wherein the extract is used to treat an organism having a virus.

2. The composition of claim 1, wherein the virus comprises an influenza virus.

3. The composition of claim 2, wherein the influenza virus comprises type A influenza.

4. The composition of claim 1, wherein the organism is a human.

5. The composition of claim 1, wherein the fucose-containing glycoprotein extract has a light absorbance of about 1.8 at O.D. 625

6. A composition comprising:

at least a fucose-containing glycoprotein fraction of Ganoderma lucidum,

wherein at least the fucose-containing glycoprotein fraction is used for the treatment of virus infections in an organism.

7. The composition of claim 6, further comprising a pharmaceutically acceptable carrier.

8. The method of claim 6, wherein the virus comprises an influenza virus.

9. The method of claim 8, wherein the influenza virus comprises type A influenza.

10. A method comprising:

administering to an organism a pharmacologically effective amount of a fucose-containing glycoprotein extract of Ganoderma lucidum to treat virus infections in an organism.

11. The method of claim 11, wherein administration of the fucose-containing glycoprotein extract occurs at least prior to the infection of the organism by the virus.

12. The method of claim 11, wherein the virus is an influenza virus.

13. The method of claim 12, wherein the influenza virus is a type A influenza virus.

14. A kit comprising:

at least a fucose-containing glycoprotein extract of Ganoderma lucidum.